北京大成（杭州）律师事务所 关于浙江英特集团股份有限公司 2025 年第二次临时股东大会的 法律意见书 致：浙江英特集团股份有限公司 北京大成（杭州）律师事务所（以下称本所）接受浙江英特集团股份有限 公司（以下称公司）的委托，指派本所律师出席公司 2025 年第二次临时股东大 会（以下称本次股东大会），本所律师根据《中华人民共和国公司法》（以下称 《公司法》）、《上市公司股东大会规则》（以下称《股东大会规则》）等法律、法 规和规范性法律文件以及《浙江英特集团股份有限公司章程》（以下称《公司章 程》）的规定，就公司本次股东大会的召集召开程序、出席会议人员的资格、召 集人的资格、表决程序和表决结果等有关事宜出具法律意见书。 为出具本法律意见书，本所律师对贵公司本次股东大会所涉及的有关事项 进行了审查，查阅了本所律师认为出具本法律意见书所必须查阅的文件，并对 有关问题进行了必要的核查和验证。 本法律意见书仅供公司本次股东大会相关事项的合法性之目的使用，不得 用于任何其他目的。本所律师同意将本法律意见书随公司本次股东大会决议一 起予以公告，并依法对本法律意见书承担相应的责任。 按照律师行业公认的业务标准、道德规范和勤 ...

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.92% on November 18, with Yao Yigou leading the drop [1] - The Shanghai Composite Index closed at 3939.81, down 0.81%, while the Shenzhen Component Index closed at 13080.49, down 0.92% [1] Stock Performance - Notable gainers included: - Ren Da Medical (603108) with a closing price of 15.97, up 2.90% and a trading volume of 278,200 shares, totaling 442 million yuan [1] - People's Tongtai (600829) with a closing price of 17.72, up 6.49% and a trading volume of 1,148,700 shares, totaling 1.902 billion yuan [1] - Major decliners included: - Yao Yigou (300937) with a closing price of 33.95, down 6.37% and a trading volume of 115,000 shares, totaling 396 million yuan [2] - Luhua Pharmaceutical (002788) with a closing price of 10.29, down 5.86% and a trading volume of 467,300 shares, totaling 489 million yuan [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 706 million yuan from institutional investors, while retail investors contributed a net inflow of 705 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing while retail investors remained active [2] Individual Stock Capital Flow - Ren Da Medical (603108) had a net inflow of 49.2 million yuan from institutional investors, while retail investors saw a net outflow of 65.5 million yuan [3] - Yao Yigou (300937) experienced a significant net outflow of 560.4 million yuan from institutional investors [3] - The data reflects varying levels of investor confidence across different stocks within the sector [3]

| 证券代码：000411 | 证券简称：英特集团 | 公告编号：2025-052 | | --- | --- | --- | | 债券代码：127028 | 债券简称：英特转债 | | 浙江英特集团股份有限公司 关于召开 2025 年第二次临时股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 浙江英特集团股份有限公司（以下简称"公司"）于 2025 年 11 月 6 日在证券时报和巨潮资讯网上 披露了《关于召开 2025 年第二次临时股东大会的通知》（公告编号：2025-050）。本次股东大会采用现 场表决与网络投票相结合的方式召开，根据中国证监会《关于加强社会公众股股东权益保护的若干规 定》，现发布关于召开 2025 年第二次临时股东大会的提示性公告。 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 11 月 21 日 9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投票的具体时间为 2025 年 11 月 21 日 9:15 至 15:00 的任意时间 ...

Market Overview - The pharmaceutical commercial sector experienced a decline of 1.62% on November 17, with Luyuan Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3972.03, down 0.46%, while the Shenzhen Component Index closed at 13202.0, down 0.11% [1] Stock Performance - Notable gainers included: - Renmin Tongtai (600829) with a closing price of 16.64, up 9.98% and a trading volume of 768,000 shares, totaling 1.276 billion yuan [1] - Other stocks in the sector showed mixed results, with several companies like Shanghai Pharmaceuticals (601607) and Guoyao Yizhi (000028) experiencing declines of 1.20% and 1.53% respectively [1] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 875 million yuan from institutional investors, while retail investors contributed a net inflow of 674 million yuan [2] - The data indicates that retail investors were more active in the market compared to institutional investors during this period [2] Individual Stock Capital Flow - Key stocks with significant capital flow include: - Shuyuan Pingmin (301017) with a net inflow of 17.85 million yuan from institutional investors, while retail investors had a net outflow of 35.94 million yuan [3] - Nanjing Pharmaceutical (600713) had a net inflow of 17.30 million yuan from institutional investors, but also saw outflows from retail investors [3] - Guoyao Yizhi (000028) and Shanghai Pharmaceuticals (601607) also experienced mixed capital flows, with institutional inflows but retail outflows [3]

Core Viewpoint - On November 17, a total of 17 listed companies will have their restricted shares unlocked, with a total market value of approximately 22.745 billion yuan [1] Summary by Category Restricted Shares Unlocking - The total number of restricted shares unlocking on this date is significant, with a total market value of about 22.745 billion yuan [1] - Specific companies and their respective unlocking details include: - Yingte Group (000411): 273,600 shares from equity incentive [1] - East China Pharmaceutical (000963): 1,630,300 shares from equity incentive [1] - Innovation New Materials (600361): 2.867 billion shares from other types [1] - Fida Environmental Protection (600526): 152 million shares with extended lock-up period [1] - New Mileage (002219): 8.7 million shares from equity incentive [1] - Anke Bio (300009): 12.3941 million shares from equity incentive [1] - Songcheng Performance (300144): 2.16 million shares from equity incentive [1] - Keheng Co., Ltd. (300340): 511,400 shares from equity incentive [1] - Haoxiangni (002582): 1 million shares from equity incentive [1] - Zhongzhi Technology (301361): 2.252 million shares from pre-issue [1] - Jack Co., Ltd. (603337): 2.4576 million shares from equity incentive [1] - Tian'ao Electronics (002935): 105,400 shares from equity incentive [1] - Huatuo Cable (605196): 556,000 shares from equity incentive [1] - Yongshuntai (001338): 266 million shares from pre-issue [1] - New World (301277): 149 million shares from pre-issue [1] - Yongxi Electronics (688362): 130 million shares [1] - Kangxi Communication (688653): 3.184 million shares [1]

浙江英特集团股份有限公司 | 证券代码：000411 | 证券简称：英特集团 | 公告编号：2025-051 | | --- | --- | --- | | 债券代码：127028 | 债券简称：英特转债 | | 关于公司2025年度第三期超短期融资券发行完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 2024年4月28日，浙江英特集团股份有限公司（以下简称"公司"或"英特集团"）收到中 国银行间市场交易商协会《接受注册通知书》（中市协注[2024]SCP147号）：中国银行间市场 交易商协会于2024年4月19日召开2024年第51次注册会议，决定接受英特集团超短期融资券 注册，明确英特集团超短期融资券注册金额为20亿元，注册额度自通知书落款之日起2年内 有效，在注册有效期内可分期发行超短期融资券。 通过"信用中国"网站查询，公司不是失信责任主体。 本期超短期融资券发行情况的有关文件详见上海清算所（www.shclearing.com.cn）和中 国货币网(www.chinamoney.com.cn)。 特此公告。 浙江英特集团股份有限公司董事会 ...

Core Insights - The pharmaceutical commercial sector experienced a rise of 1.05% on November 14, with significant gains led by the stock of Jiyu Pingmin, which surged by 20.03% [1] - The Shanghai Composite Index closed at 3990.49, down 0.97%, while the Shenzhen Component Index closed at 13216.03, down 1.93% [1] Stock Performance - Jiyu Pingmin (301017) closed at 16.66 with a gain of 20.03%, trading volume of 141,800 shares and a transaction value of 227 million [1] - Renmin Tongtai (600829) and Kaikai Industry (600272) also saw notable increases of 10.04% and 10.03%, respectively [1] - The pharmaceutical sector's stocks showed a mixed performance, with some stocks like Jianfa Zhixin (301584) and Runda Medical (603108) declining by 3.33% and 1.59% respectively [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 497 million from institutional investors, while retail investors contributed a net inflow of 590 million [2][3] - The main stocks experiencing significant net inflows from retail investors included Jiyu Pingmin and Kaikai Industry, while institutional investors showed a preference for stocks like Kaikai Industry [3]

Core Insights - The three major stock indices experienced a slight decline on November 12, with the pharmaceutical sector showing strength, particularly with stocks like Yaoyigou hitting the daily limit and Jianfa Zhixin rising over 10% [2] Industry Summary - The National Disease Control and Prevention Administration held a press conference on November 10 regarding the prevention and control of acute respiratory infectious diseases during the autumn and winter seasons. Monitoring data indicates that flu activity in China is currently on the rise, with the H3N2 subtype accounting for over 95% of cases [2] - The China Securities Journal reports that the trend of innovation going global is clear, with the pharmaceutical sector leading the way. The ongoing reform in drug review processes is yielding benefits, and the Chinese innovative drug industry has entered a 2.0 era, shifting from "import imitation" to "innovation output" [2] - The report highlights that the development of innovative drugs is supported by improved investment and financing data, indicating a new cycle for CXO and upstream sectors. The potential for medical devices and other categories to also expand internationally is promising [2]

Core Viewpoint - The pharmaceutical commercial sector experienced a significant surge, with the sector index reaching a new high for the year [1]. Group 1: Market Performance - Individual stocks such as YaoYigou saw a rapid increase, hitting a 20% limit up within approximately 4 minutes of opening [3]. - HeFu China achieved a limit up after a strong opening, marking 11 limit ups in the last 12 trading days [3]. - RenMin TongTai opened with a limit up, achieving three consecutive limit ups [3]. Group 2: Stock Details - YaoYigou: +19.99%, previous amount 3.75 billion, current market cap 33.59 billion, current price 35.14 [4]. - JianFa ZhiXin: +14.86%, previous amount 9.66 billion, current market cap 154.01 billion, current price 36.55 [4]. - RenMin JianTan: +10.04%, previous amount 59.297 million, current market cap 72.49 billion, current price 12.50 [4]. - HeLiang China: +10.02%, previous amount 12.16 billion, current market cap 79.97 billion, current price 20.09 [4]. - DaShenLin: +4.67%, previous amount 3.23 billion, current market cap 222.1 billion, current price 19.50 [4]. - YiFeng Pharmacy: +2.80%, previous amount 3.71 billion, current market cap 303.0 billion, current price 24.99 [4].

Core Viewpoint - The pharmaceutical commercial sector experienced a significant surge, with the sector index reaching a new high for the year [1]. Group 1: Market Performance - Individual stocks such as YaoYigou saw a rapid increase, hitting a 20% limit up within just 4 minutes of opening [3]. - HeFu China opened high and quickly reached a limit up, achieving 11 limit up days in the last 12 trading days [3]. - RenMin TongTai opened with a limit up and secured three consecutive limit up days [3]. Group 2: Stock Details - YaoYigou (300937) increased by 19.99%, with a total amount of 3.75 billion and a market cap of 33.59 billion, currently priced at 35.11 [4]. - JianFa ZhiXin (301584) rose by 14.86%, with a total amount of 9.66 billion and a market cap of 154 billion, currently priced at 36.55 [4]. - RenMin TongTai (600829) increased by 10.04%, with a total amount of 59.297 million and a market cap of 72.49 billion, currently priced at 12.50 [4]. - HeFu China (603122) rose by 10.02%, with a total amount of 12.16 billion and a market cap of 79.97 billion, currently priced at 20.09 [4]. - Other stocks like DaCanLin (603233) and YingTe Group (000411) also showed positive performance, with increases of 4.67% and 2.71% respectively [4].